Sanofi's Sarclisa Set To Expand Front-Line Multiple Myeloma Use In EU Following Positive CHMP Opinion Backed By MRD And PFS Gains

Sanofi SA Sponsored ADR -0.84%

Sanofi SA Sponsored ADR

SNY

47.62

-0.84%

  • Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd alone
  • If approved, it would represent the fourth indication in the EU and second in the front-line setting globally


 

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.